In a pooled analysis of FIGHT and EXSCEL (Exenatide Study of Cardiovascular Event Lowering) trial, which studied exenatide in T2DM patients with or without CV disease, GLP‐1 RA use was associated with a higher risk of HF hospitalization in patients with LVEF <40% (odds ratio [OR] 1.49, 95% CI 1.05–2.10).36 Here, GLP1R is linked to type 2 diabetes mellitus.